Glycogen Storage Disease Type V (McArdle's Disease)

Subscribe to Selected New Research on Glycogen Storage Disease Type V

241 relevant articles (13 outcomes, 27 trials/studies) found for this Disease

Description: Glycogenosis due to muscle phosphorylase deficiency. Characterized by painful cramps following sustained exercise.

Also Known As:

McArdle's Disease; McArdle Disease; Deficiency, Muscle Phosphorylase; Muscle Phosphorylase Deficiency; 5, Glycogenosis; 5s, Glycogenosis; Deficiencies, Muscle Phosphorylase; Disease, McArdle; Disease, McArdle's; Glycogenosis 5s; McArdles Disease; Muscle Phosphorylase Deficiencies; Phosphorylase Deficiencies, Muscle; Phosphorylase Deficiency, Muscle; Glycogenosis 5

Relationship Network

Disease Context: Research Results

Congenital, Hereditary, and Neonatal Diseases and Abnormalities: 421

Inborn Genetic Diseases: 549

Inborn Errors Metabolism: 402

Inborn Errors Carbohydrate Metabolism

Glycogen Storage Disease: 920

Glycogen Storage Disease Type V: 241

Nutritional and Metabolic Diseases

Metabolic Diseases: 1267

Inborn Errors Metabolism: 402

Inborn Errors Carbohydrate Metabolism

Glycogen Storage Disease: 920

Glycogen Storage Disease Type V: 241

Related Diseases

1.	Mitochondrial Myopathies (Mitochondrial Myopathy)
2.	Glycogen Storage Disease Type VII (Tarui's Disease)
3.	Muscular Diseases (Myopathy)
4.	Glycogen Storage Disease Type V (McArdle's Disease)
5.	Myoglobinuria

Experts

1.	Arenas, J: 9 articles (12/2005 - 01/2000)
2.	Martín, M A: 7 articles (01/2004 - 01/2000)
3.	Rubio, J C: 7 articles (01/2004 - 01/2000)
4.	Andreu, A L: 6 articles (12/2005 - 02/2000)
5.	Campos, Y: 6 articles (11/2001 - 01/2000)
6.	Cabello, A: 5 articles (11/2001 - 01/2000)
7.	Haller, Ronald G: 4 articles (06/2008 - 06/2002)
8.	Vissing, John: 4 articles (06/2008 - 06/2002)
9.	Cabello, Ana: 3 articles (02/2008 - 06/2005)
10.	Andreu, Antoni L: 3 articles (02/2008 - 09/2003)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Glycogen Storage Disease Type V:

1.	Glucagon (Glukagon)FDA Link 11/01/1984 - "Metabolic basis of improved exercise tolerance: muscle phosphorylase deficiency after glucagon administration." 12/01/1985 - "Depot-glucagon in the treatment of McArdle's disease." 11/26/1982 - "McArdle's disease: therapeutic use of depot-glucagon]" 09/01/1984 - "Pretreatment with glucagon relieved patients with McArdle disease from muscular symptoms during exercise and enhanced exercise performance, though it did not produce any improvement in patients with Tarui disease" 09/01/1984 - "A comparative study on glucagon effect between McArdle disease and Tarui disease." Order ALL the reference details at left...
2.	Muscle Form Glycogen Phosphorylase (Myophosphorylase)IBA 01/01/2007 - "Lower-dose CrM supplementation in patients with McArdle's disease (myophosphorylase deficiency) improved exercise capacity, yet higher doses actually showed some indication of worsened function" 11/01/2002 - "Molecular genetic study of myophosphorylase deficiency (McArdle's disease) in two Yemenite-Jewish families." 02/01/2000 - "OBJECTIVE: To investigate the degree of genetic heterogeneity of myophosphorylase deficiency (McArdle disease) in Spain through molecular studies of 10 new patients" 06/15/1979 - "McArdle's disease: a study on the molecular basis of two different etiologies of myophosphorylase deficiency." 04/01/2008 - "We evaluated the molecular and biochemical adaptations in substrate metabolism (glycolysis, electron transport chain, tricarboxylic acid cycle, beta-oxidation) in response to myophosphorylase deficiency in skeletal muscle from 13 patients with McArdle's disease (MD) and 13 age-matched controls" Order ALL the reference details at left...
3.	Glucose (Dextrose)FDA LinkGeneric 06/01/2002 - "In this study, six patients with McArdle's disease and six matched control subjects were subjected to an oral glucose tolerance test and a euglycemic-hyperinsulinemic clamp" 05/13/2008 - "IV glucose administration appeared to improve exercise tolerance in the patient with PHK deficiency, but not to the same extent as in the patients with McArdle disease" 09/01/2002 - "CONCLUSIONS: First, the spontaneous second wind and the glucose-induced second second wind in McArdle disease are due to substrate-dependent increases in muscle oxidative capacity" 09/01/2002 - "Spontaneous "second wind" and glucose-induced second "second wind" in McArdle disease: oxidative mechanisms." 05/01/1992 - "Hormonal, metabolic, and cardiovascular responses to 21 min of cycling in three saline- or glucose-infused men with McArdle's disease were compared with those of matched controls to elucidate whether mobilization of extramuscular fuel is enhanced to compensate for the lack of intramuscular glycogenolysis in patients with McArdle's disease" Order ALL the reference details at left...
4.	Adenosine Triphosphate (ATP)IBA 07/01/1990 - "These findings suggest that glucose infusion to patients with McArdle's disease ameliorates excessive ATP degradation in exercising muscles." 12/01/1985 - "The results suggest that alterations in the levels of muscle PCr and Pi but not ATP are involved in the muscle fatigue in McArdle's disease and the improved exercise performance during glucose infusion." 07/01/1990 - "Glucose infusion abolishes the excessive ATP degradation in working muscles of a patient with McArdle's disease." 07/01/2007 - "McArdle's disease is caused by genetic defects of the muscle-specific isozyme of glycogen phosphorylase, which block ATP formation from glycogen in skeletal muscle" 05/01/2001 - "We studied exercise-induced changes in the adenosine triphosphate (ATP), phosphocreatine (PCr), and lactate levels in the skeletal muscle of mitochondrial patients and patients with McArdle's disease" Order ALL the reference details at left...
5.	CreatineIBA 01/01/2002 - "BACKGROUND: In a recent study, we showed that administration of low-dose creatine (Cr) (60 mg/kg daily) improved work capacity in patients with McArdle disease" 07/01/2000 - "CONCLUSION: This is the first controlled study indicating that creatine supplementation improves skeletal muscle function in McArdle disease." 07/01/2007 - "Treatment of glycogenosys type V (McArdle disease) with creatine and ketogenic diet with clinical scores and with 31P-MRS on working leg muscle." 05/01/2003 - "Exercise to exhaustion in the second-wind phase of exercise in a case of McArdle's disease with and without creatine supplementation." 01/01/2002 - "Effect of high-dose creatine therapy on symptoms of exercise intolerance in McArdle disease: double-blind, placebo-controlled crossover study." Order ALL the reference details at left...
6.	Ribose (D-Ribose)IBA 03/01/1996 - "To determine whether seven days oral D-ribose would improve exercise tolerance in a group of 5 patients with McArdle's disease, we performed a double blind placebo controlled crossover trial" 03/01/1996 - "A double blind, placebo controlled, crossover trial of D-ribose in McArdle's disease." 03/01/1996 - "Patients did not like taking the ribose and D-Ribose does not appear to be of benefit to patients with McArdle's disease." 01/22/1991 - "McArdle's disease: successful symptomatic therapy by high dose oral administration of ribose." 07/01/1992 - "Ribose application has been shown to be beneficial in several clinical disease states such as myoadenylate deaminase deficiency and McArdle's disease" Order ALL the reference details at left...
7.	Verapamil (Calan)FDA LinkGeneric 09/01/1986 - "None of the patients with McArdle's disease responded to verapamil, but two patients with unclassified EMPS experienced a striking improvement in symptoms and two others showed a partial response" 09/01/1986 - "Eleven patients, comprising three cases of McArdle's disease and eight with an exertional muscle pain syndrome (EMPS) of unknown cause, entered a double-blind crossover study of verapamil and placebo" 09/01/1984 - "Trials of verapamil and dantrolene sodium in McArdle disease." Order ALL the reference details at left...
8.	Ramipril (Altace)FDA LinkGeneric 03/01/2008 - "In a double-blind, randomized, placebo-controlled trial, we assessed the efficacy of an ACE inhibitor (2.5 mg ramipril) in 8 patients with McArdle's disease" 03/01/2008 - "Randomized, placebo-controlled, double-blind pilot trial of ramipril in McArdle's disease." Order ALL the reference details at left...
9.	AMP Deaminase (Myoadenylate Deaminase)IBA 06/01/1987 - "McArdle's disease with myoadenylate deaminase deficiency: observations in a combined enzyme deficiency." 07/01/1992 - "The authors present a case report of patient with McArdle's disease, and diagnostic procedures which can be used in different diagnostic of metabolic myopathies, especially between myoadenylate deaminase deficiency and different types of gly(geno)lytic myopathies" 07/01/1992 - "Ribose application has been shown to be beneficial in several clinical disease states such as myoadenylate deaminase deficiency and McArdle's disease" 07/01/1995 - "DNA analysis showed that the child was homozygous for the mutations commonly found in both McArdle's disease and AMP deaminase deficiency" 04/01/1986 - "Ischaemic exercise test in myoadenylate deaminase deficiency and McArdle's disease: measurement of plasma adenosine, inosine and hypoxanthine." Order ALL the reference details at left...
10.	Pyruvic Acid (Pyruvate)IBA 12/01/1992 - "CONCLUSION: These results suggest that patients with McArdle's disease may improve their muscle energy production by endurance training which enhances lipid metabolism, whereas in mitochondrial myopathies, the energy production by oxidation of pyruvate or lipids may be improved only by enzymatic substitution." Order ALL the reference details at left...

Therapies and Procedures

1.	Exercise (Aerobic Exercise) 10/01/2007 - "Recent studies showed improvement in exercise capacity after regular aerobic exercise training in patients with McArdle's disease and mitochondrial myopathies" Order ALL the reference details at left...
2.	Cesarean Section (Caesarean Section) 02/01/1988 - "McArdle's disease and caesarean section." 08/01/1984 - "A case is presented of the anaesthetic management of a patient with McArdle's disease who required Caesarean section" 06/01/2002 - "Anesthesia for cesarean section in a patient with McArdle disease and hereditary dilated cardiomyopathy]" 06/01/2002 - "A caesarean section was indicated in a 29-year-old parturient affected by a muscular deficit in myophosphorylase responsible for a type V glycogen storage disease (McArdle disease)" Order ALL the reference details at left...
3.	Microelectrodes 05/01/1990 - "To determine if sympathetic activation is attenuated when muscle glycogenolysis is blocked due to myophosphorylase deficiency (McArdle's disease), an inborn enzymatic defect localized to skeletal muscle, we now have performed microelectrode recordings of MSNA in four patients with McArdle's disease during static handgrip contraction" 05/01/2003 - "To determine if lactic acid is a critical mediator of metaboreflex activation in humans, we performed microelectrode recordings of MSNA in eight patients with myophosphorylase deficiency (McArdle's disease) who cannot metabolize intramuscular glycogen and do not generate lactic acid in exercising muscles" Order ALL the reference details at left...
4.	Investigational Therapies (Experimental Therapy) 10/01/1992 - "Experimental therapies for McArdle's disease have been directed toward increasing substrate availability to exercising muscle" Order ALL the reference details at left...
5.	Lasers (Laser) 06/25/1987 - "NADH measured by laser fluorimetry in skeletal muscle in McArdle's disease." Order ALL the reference details at left...

Best Treatments:
Research Summary Report
on Glycogen Storage Disease Type V

*WARNING* This specific disease subtype has a relatively small number of significant evidence outcomes. You may proceed to order anyway, or go back to the search field and enter a more general type of the target illness. Once your report has been ordered, however, we can't refund the purchase.

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 13 Outcomes
Top 200 Key Drugs and Biologics
Top 7 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>